Naproxen immediate-release - Oxford Pharmascience

Drug Profile

Naproxen immediate-release - Oxford Pharmascience

Alternative Names: Gastric-safe naproxen; Immediate release naproxen - Oxford Pharmasciences; OXP 005; OXPzero™ naproxen

Latest Information Update: 06 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Oxford Pharmascience
  • Class Antipyretics; Antirheumatics; Naphthaleneacetic acids; Nonsteroidal anti-inflammatories; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Musculoskeletal pain

Most Recent Events

  • 27 Sep 2017 Suspended - Phase-I for Musculoskeletal pain (In volunteers) in United Kingdom, pending conclusion of a strategic review (PO)
  • 09 Nov 2016 Oxford Pharmascience's naproxen immediate-release is available for market licensing as of 09 Nov 2016. www.oxfordpharmascience.com
  • 09 Nov 2016 Oxford Pharmascience files for patent protection with UK Intellectual Property Office for OXPzero™ technology in United Kingdom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top